The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing a Funding Opportunity Announcement (FOA) for a Cooperative Agreement. This opportunity aims to address the issue of nitrosamine impurities in human drugs and improve the safety of these drugs. The proposed work will involve the identification and evaluation of possible approaches to addressing nitrosamine impurities in drugs.
Nitrosamine impurities pose risks to public health, and while significant efforts have been made in this area, further research, development, and refinement of translational and implementable practices are needed. The goal is to protect the public from nitrosamine risks while ensuring continued safe access to critical therapeutic drugs.
In addition to the research and development work, the award recipient will also assess how to ensure the continuation of this research and practices development among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.
For more information, please refer to the Funding Opportunity Announcement.